Serum Clusterin Level as a diagnostic and prognostic marker for Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the third deadliest and fifth most common cancer worldwide, despite the widespread use of surveillance programs in at risk populations, more than half of HCC cases are diagnosed late, and curative therapies such as surgical resection, radiofrequency ablation (RFA) or TACE are possible in less than 30% of patients. In Egypt, HCC is the first most common cancer in men and the second most common cancer in women according to GLOBOCAN 2012 (WHO project for Globalal Cancer statics estimation) Although AFP is a useful serological marker for HCC diagnosis, the false negative rate or false positive rate with AFP level alone may be as high as 40 %, especially for its early diagnosis or the finding of small size HCC, also AFP is elevated in pregnancy and other types of cancer such as germ cell, stomach, biliary tract and pancreatic tumors • Clusterin (CLU) is a 449 amino acid, heterodimeric glycoprotein with a plausible role in the regeneration, migration, and anti-apoptosis of tumor cells ; our study aiming to evaluate the significance of Clusterin as a diagnostic and Prognostic biomarker for HCC patients related cirrhosis and its ability in recurrence prediction before and after interventional therapy where (65) Egyptian patients were recruited from department of Internal Medicine